WWOX and urinary bladder cancer: Iliopoulos et al. [29] show that changes in WWOX expression in lung, breast, and bladder cancers are not only due to genomic alterations, such as loss of heterozygosity and homozygous deletions, but also epigenetic modifications, such as promoter hypermethylation.